Literature DB >> 25411106

Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?

Michele M Mumaw1, Marvin T Nieman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25411106      PMCID： PMC4321948          DOI： 10.1161/ATVBAHA.114.304727

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  17 in total

1.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

2.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

3.  Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets.

Authors:  Dongjun Li; Lauren D'Angelo; Massiel Chavez; Donna S Woulfe
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

4.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

5.  Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.

Authors:  Andrew J Leger; Suzanne L Jacques; Jehangir Badar; Nicole C Kaneider; Claudia K Derian; Patricia Andrade-Gordon; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2006-02-27       Impact factor: 29.690

6.  Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Authors:  Benjamin M Scirica; Marc P Bonaca; Eugene Braunwald; Gaetano M De Ferrari; Daniel Isaza; Basil S Lewis; Felix Mehrhof; Piera A Merlini; Sabina A Murphy; Marc S Sabatine; Michal Tendera; Frans Van de Werf; Robert Wilcox; David A Morrow
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

7.  Genetic and environmental contributions to platelet aggregation: the Framingham heart study.

Authors:  C J O'Donnell; M G Larson; D Feng; P A Sutherland; K Lindpaintner; R H Myers; R A D'Agostino; D Levy; G H Tofler
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

8.  Racial differences in long-term survival among patients with coronary artery disease.

Authors:  Kevin L Thomas; Emily Honeycutt; Linda K Shaw; Eric D Peterson
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

9.  Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis.

Authors:  Jarett D Berry; Kiang Liu; Aaron R Folsom; Cora E Lewis; J Jeffrey Carr; Joseph F Polak; Steven Shea; Stephen Sidney; Daniel H O'Leary; Cheeling Chan; Donald M Lloyd-Jones
Journal:  Circulation       Date:  2009-01-12       Impact factor: 29.690

10.  High-resolution crystal structure of human protease-activated receptor 1.

Authors:  Cheng Zhang; Yoga Srinivasan; Daniel H Arlow; Juan Jose Fung; Daniel Palmer; Yaowu Zheng; Hillary F Green; Anjali Pandey; Ron O Dror; David E Shaw; William I Weis; Shaun R Coughlin; Brian K Kobilka
Journal:  Nature       Date:  2012-12-09       Impact factor: 49.962
View more
  4 in total

1.  Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Authors:  Michele M Mumaw; Maria de la Fuente; Amal Arachiche; James K Wahl; Marvin T Nieman
Journal:  Thromb Res       Date:  2015-04-09       Impact factor: 3.944

2.  Hormones, age, and sex affect platelet responsiveness in vitro.

Authors:  Jamie B Hadley; Marguerite R Kelher; Julia R Coleman; Kathleen K Kelly; Larry J Dumont; Orlando Esparza; Anirban Banerjee; Mitchell J Cohen; Kenneth Jones; Christopher C Silliman
Journal:  Transfusion       Date:  2022-08-05       Impact factor: 3.337

Review 3.  Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.

Authors:  Gamariel Rwibasira Rudinga; Ghulam Jilany Khan; Yi Kong
Journal:  Int J Mol Sci       Date:  2018-02-14       Impact factor: 5.923

Review 4.  Genomics and transcriptomics of megakaryocytes and platelets: Implications for health and disease.

Authors:  Marlie H Fisher; Jorge Di Paola
Journal:  Res Pract Thromb Haemost       Date:  2018-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.